Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;40(7):1100-1108.
doi: 10.1038/s41372-020-0605-5. Epub 2020 Feb 28.

Evaluation of the economic impact of modified screening criteria for retinopathy of prematurity from the Postnatal Growth and ROP (G-ROP) study

Collaborators, Affiliations

Evaluation of the economic impact of modified screening criteria for retinopathy of prematurity from the Postnatal Growth and ROP (G-ROP) study

John A F Zupancic et al. J Perinatol. 2020 Jul.

Abstract

Importance: The Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study showed that the addition of postnatal weight gain to birth weight and gestational age detects similar numbers of infants with ROP, but requires examination of fewer infants.

Objective: To determine the incremental cost-effectiveness of screening with G-ROP compared with conventional screening.

Design, setting and participants: We built a microsimulation model of a 1-year US birth cohort <32 weeks gestation, using data from the G-ROP study. We obtained resource utilization estimates from the G-ROP dataset and from secondary sources, and test characteristics from the G-ROP cohort.

Results: Among 78,281 infants nationally, screening with G-ROP detected ~25 additional infants with Type 1 ROP. This was accomplished with 36,233 fewer examinations, in 14,073 fewer infants, with annual cost savings of approximately US$2,931,980 through hospital discharge.

Conclusions: Screening with G-ROP reduced costs while increasing the detection of ROP compared with current screening guidelines.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Decision tree model for the base case (Discharge) analysis
Figure 2.
Figure 2.
Differences in mean costs and effects between Conventional Screening and G-ROP screening cohorts for the base case (Discharge), cost per case of Type 1 ROP detected. Each point represents one run of the simulation model as described in the text. Ellipse represents 95% confidence bound for joint distribution of cost and effectiveness.

References

    1. Early Treatment For Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: Results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121(12):1684–94. - PubMed
    1. Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Quintos M, et al. The incidence and course of retinopathy of prematurity: Findings from the early treatment for retinopathy of prematurity study. Pediatrics. 2005;116(1):15–23. - PubMed
    1. Davitt BV, Dobson V, Good WV, Hardy RJ, Quinn GE, Siatkowski RM, et al. 15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity. Archives of Ophthalmology. 2005;123:311–8. - PubMed
    1. Fierson WM, American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2018;142(6): e20183061 - PubMed
    1. Binenbaum G, Ying GS, Quinn GE, Huang J, Dreiseitl S, Antigua J, et al. The CHOP postnatal weight gain, birth weight, and gestational age retinopathy of prematurity risk model. Arch Ophthalmol. 2012;130(12):1560–5. - PubMed

Publication types